18C Stock Overview
A phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
GB Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0055 |
| 52 Week High | US$0.011 |
| 52 Week Low | US$0.004 |
| Beta | 0.34 |
| 1 Month Change | 10.00% |
| 3 Month Change | 22.22% |
| 1 Year Change | -42.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| 18C | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.1% | 1.6% |
| 1Y | -42.1% | -17.5% | 7.3% |
Return vs Industry: 18C underperformed the German Pharmaceuticals industry which returned -21.6% over the past year.
Return vs Market: 18C underperformed the German Market which returned 6.5% over the past year.
Price Volatility
| 18C volatility | |
|---|---|
| 18C Average Weekly Movement | 18.0% |
| Pharmaceuticals Industry Average Movement | 7.0% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 18C's share price has been volatile over the past 3 months.
Volatility Over Time: 18C's weekly volatility has decreased from 24% to 18% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 3 | John Poss | www.gbsciences.com |
GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson’s disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs.
GB Sciences, Inc. Fundamentals Summary
| 18C fundamental statistics | |
|---|---|
| Market cap | €2.54m |
| Earnings (TTM) | -€3.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 18C overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 18C income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.03m |
| Earnings | -US$4.03m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0099 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -31.2% |
How did 18C perform over the long term?
See historical performance and comparison